Day: April 26, 2021

The Novian IT infrastructure and software services group had aggregated revenue of EUR 24.1 million in 2020, or 2.6% more than in 2019. The group’s aggregated EBITDA was EUR 1.8 million and compared to 2019 grew 14.9%. The Novian group’s net profit for the year, excluding nonrecurring and atypical losses in the value of investments, was EUR 0.6 million and increased 54.5% compared to 2019. Calculation of the results of the Novian group is based on the audited 2020 results of Novian Technologies, Novian Systems and Zissor. “Last year was a challenging time for organizations. Due to the restrictions of the pandemic, digitalization became even more relevant – from remote work to the ‘smart’ data, artificial intelligence and automation possibilities that enabled further business continuity and resilience. In that context, we are striving...

IT infrastruktūros paslaugų ir programavimo grupė „Novian“ per 2020 metus uždirbo 24,1 mln. eurų agreguotų pajamų arba 2,6 proc. daugiau nei per 2019 metus. Grupės agreguota EBITDA siekė 1,8 mln. eurų ir, lyginant su 2019 m., išaugo 14,9 proc. „Novian“ grupės grynasis pelnas, eliminavus vienkartinius ir netipinius investicijų nuvertėjimus,  šiuo laikotarpiu sudarė 0,6 mln. eurų ir atitinkamai padidėjo 54,5 proc. Apskaičiuojant „Novian“ grupės rezultatus, vertinami audituoti bendrovių „Novian Technologies“, „Novian Systems“ ir „Zissor“ 2020 m. rezultatai. „Praėjusieji metai organizacijoms ir verslui buvo iššūkių laikas – dėl pandemijos ribojimų skaitmenizacija tapo dar aktualesnė – pradedant nuotoliniu darbu ir baigiant „protingųjų“ duomenų, dirbtinio intelekto ir automatizacijos galimybėmis, leidusiomis išlaikyti veiklos tęstinumą ir...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 26 April 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (the “Company”) on 15 April 2021 regarding publication of a prospectus and commencement of a subsequent offering of up to 2,710,377 new ordinary shares in the Company at a subscription price of NOK 53.00 per share (the “Subsequent Offering“). The subscription period in the Subsequent Offering will expire today, 26 April 2021, at 16:30 hours (CEST). Correctly completed subscription...

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trialRespiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants.1–5 Nirsevimab is being investigated as a first-in-class single dose immunization to provide protection for all infants entering their first RSV season. Nirsevimab met its Phase 3 primary endpoint earlier than anticipated; regulatory submissions for all-infant indication to begin in 2022.PARIS – April 26, 2021 – Positive topline results from the Phase 3 MELODY trial showed nirsevimab reduced lower respiratory tract infections (LRTI) requiring medical attention (inpatient or outpatient) due to respiratory syncytial virus (RSV) in healthy preterm and term infants. RSV is the most common cause of LRTI and the leading cause of hospitalizations...

Un essai de phase III montre que le nirsevimab protège les nourrissons en bonne santé contre les infections causées par le virus respiratoire syncytial Les infections par le virus respiratoire syncytial (VRS) sont la principale cause d’hospitalisation des nourrissons1–5. L’administration d’une dose de nirsvimab, premier vaccin de sa classe pharmacothérapeutique, est étudiée pour déterminer si elle confère une protection à tous les nourrissons pendant la première saison VRS de leur vie. L’essai de phase III du nirsevimab a atteint son critère d’évaluation principal plus tôt que prévu ; les soumissions réglementaires en vue de son indication pour tous les nourrissons devraient débuter en 2022.PARIS – Le 26 avril 2021 – Les premiers résultats de l’essai MELODY de phase III montrent que le nirsevimab réduit les infections des voies...

Oslo, Norway – 26 April 2021 – IDEX Biometrics ASA, (OSE: IDEX and Nasdaq: IDBA) has filed its 2020 annual report on form 20-F with the U.S. Securities and Exchange Commision (SEC). The report includes audited consolidated financial statements for the year ended 31 December 2020. The 2020 annual report on form 20-F is enclosed in pdf file. The 2020 annual report to Norway, dated 14 April 2021 and the 2020 annual report on form 20-F are available at the company’s web site www.idexbiometrics.com. All SEC filings made available electronically by IDEX Biometris may be obtained from the SEC’s website at www.sec.gov For further information contact: Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: + 47 918 00186 Brett L Perry, U.S. Investor RelationsE-mail: bperry@sheltongroup.comTel: + 1 214 272 0070 About IDEX...

26 April 2021 G4S plc (“G4S” or the “Company”) Notification of Change in Issuer Rating and Issue Rating G4S notes that following its announcement of 26 February 2021 placing the Company’s ‘BBB-/A-3’ ratings on Credit Watch negative, S&P Global Ratings announced on 22 April 2021, that it had downgraded:G4S plc’s issuer credit rating; and G4S plc’s senior unsecured debt rating (in respect of senior bonds issued by, or guaranteed by, G4S plc),in each case, from BBB- to B. On 8 December 2020 the boards of directors managing Allied Universal Topco LLC (“Allied Universal”) and of G4S announced that they had reached agreement on the terms of a recommended cash offer, to be made by Atlas UK Bidco Limited (“Allied Bidco”), a newly incorporated entity that is indirectly controlled by Allied Universal, to acquire the entire issued and to...

PRESS RELEASE Ergomed expands operations in Japan New legal entity and regional office established in Tokyo responding to client demand Guildford, UK – 26 April 2021: Ergomed plc (LSE: ERGO) (“Ergomed” or the “Company”), a company focused on providing specialised services to the pharmaceutical industry, announces that its PrimeVigilance business, a global leader in the provision of pharmacovigilance and medical information services, has established its new legal entity and regional office in Japan and is fully operational from 26 April 2021. The new subsidiary company, trading as PrimeVigilance Japan KK, is based in Tokyo and offers a comprehensive range of pharmacovigilance services, including a dedicated Japanese safety database. Full Japanese language Medical Information services are also provided. This expansion...